



**MOLECULAR ANALYSIS OF ACUTE AND
CHRONIC DUCK HEPATITIS B VIRUS (DHBV)
INFECTIONS IN DUCKS**

Huey Chi LOW

B.Sc. (Biomedical Science), B.Sc. (Hons)

A thesis submitted to the University of Adelaide
in fulfilment of the requirements for the degree of Doctor of Philosophy

**Discipline of Microbiology and Immunology
School of Molecular and Biomedical Science
The University of Adelaide
South Australia**

April 2012

Dedication

To my loving family

who never gave up on me over all these years

Dad

For your silent encouragement and support (financially and emotionally)
Words just simply could not describe how much you mean to me

Mom

For always sacrificing your all to give me the best in everything
I could never ever repay you for all you have done for me

Elder sis

For always being there for me, cheering me up, and trying to help as best as you can
I could not hope for a better, crazier sister than you

This belongs to you all as much as it belongs to me

To God my Heavenly Father be all the glory in the name of His Son

*Even youths grow tired and weary, and young men stumble and fall;
But those who hope in the Lord will renew their strength.
They will soar on wings like eagles;
They will run and not grow weary, they will walk and not be faint.
Isaiah 40:31*

Table of Contents

Abstract.....	i
Declaration of originality and consent.....	vii
Publications and presentations resulting from this thesis.....	viii
Acknowledgements	x
Abbreviations	xiv
Chapter 1: Introduction	1
1.1. Epidemiology of hepatitis B virus	1
1.2. Hepadnaviruses.....	1
1.2.1. The Hepadnaviridae family	1
1.2.2. HBV virion structure	2
1.2.3. HBV genome	3
1.2.3.1. HBV genomic structure	3
1.2.3.2. Open reading frames present on the HBV genome	3
1.2.4. HBV replication.....	4
1.2.4.1. HBV attachment and entry	4
1.2.4.2. Transcription and replication.....	5
1.2.4.3. Encapsidation, reverse transcription, budding and release.....	5
1.3. HBV mode of transmission	7
1.4. HBV infection outcomes	8
1.4.1. Acute HBV infection.....	9
1.4.1.1. Serological markers during acute HBV infection	9
1.4.1.2. Immune responses during acute HBV infection.....	9
1.4.1.3. Occult HBV infection.....	10
1.4.2. Chronic HBV infection.....	11
1.4.2.1. Serological markers during chronic HBV infection	11
1.4.2.2. Immune responses during chronic HBV infection	12
1.4.2.3. Chronic HBV-induced liver pathology	13
1.5. HBV vaccines and treatments.....	13
1.5.1. HBV vaccines	13
1.5.2. HBV treatments	14
1.5.2.1. Immuno-modulators	14
1.5.2.2. Nucleoside/nucleotide analogues	15
1.5.2.3. Combination therapies and future potential therapies	16
1.6. Clearance of cccDNA from infected hepatocytes	16
1.6.1. Cytolytic hepatocyte killing	16

1.6.2.	Non-cytolytic hepatocyte curing	17
1.7.	Clonal proliferation of hepatocytes	19
1.7.1.	Clonal proliferation of hepatocytes during acute HBV infection.....	19
1.7.2.	Clonal proliferation of hepatocytes during chronic HBV infection	20
1.8.	Integration of HBV DNA into the host genome.....	21
1.8.1.	Detection of integrated virus-cell junctions.....	22
1.9.	Animal models for the study of HBV	24
1.10.	Study aims and outline	27
Chapter 2: Materials and Methods		40
2.1.	Animals.....	40
2.2.	Virus stock.....	40
2.3.	Procedures involving ducks.....	40
2.3.1.	Inoculation of ducks with DHBV	40
2.3.2.	Serum sample collection.....	41
2.3.2.1.	Venipuncture	41
2.3.2.2.	Blood serum extraction.....	41
2.3.3.	Liver tissue collection.....	41
2.3.3.1.	Liver biopsy	41
2.3.3.2.	Autopsy.....	42
2.3.4.	Tissue sample processing	42
2.3.4.1.	Tissue fixation, embedding and sectioning	42
2.3.4.1.1.	Ethanol:acetic acid.....	42
2.3.4.1.2.	Formalin	43
2.3.4.1.3.	70% ethanol	43
2.3.4.2.	Liver tissue processing	43
2.4.	Histology and immunohistochemical analysis of tissue sections.....	43
2.4.1.	Haematoxylin and eosin (H&E) staining.....	43
2.4.2.	Immunohistochemical detection of DHBsAg	44
2.4.3.	Periodic acid-Schiff diastase (PAS-D) staining of Kupffer cells	45
2.4.4.	Immunohistochemical detection of proliferating cell nuclear antigen (PCNA)..	45
2.4.5.	Statistical analysis	46
2.5.	Serologic assays.....	46
2.5.1.	DHBV DNA extraction from serum.....	46
2.5.2.	Detection of DHBsAg by ELISA	46
2.5.3.	Detection of anti-DHBC antibodies by ELISA	47
2.5.4.	Detection of anti-DHBs antibodies by ELISA	48

2.6.	Liver DNA extraction.....	48
2.6.1.	DNeasy blood and tissue kit.....	48
2.6.2.	ChargeSwitch gDNA mini tissue kit.....	49
2.6.3.	Total DNA extraction.....	49
2.6.4.	Low melting temperature agarose gel electrophoresis and purification of high molecular weight cellular DNA.....	49
2.6.5.	Nuclear DNA extraction.....	50
2.6.6.	High MW DNA extraction.....	51
2.6.6.1.	High MW DNA extraction I.....	51
2.6.6.2.	High MW DNA extraction II.....	51
2.6.6.3.	High MW DNA extraction III.....	52
2.6.7.	cccDNA extraction method.....	52
2.7.	Plasmid DNA extraction.....	52
2.7.1.	Mini prep.....	52
2.7.2.	Maxi prep.....	52
2.8.	DNA analysis.....	53
2.8.1.	Measurement of DNA concentration.....	53
2.8.2.	Restriction enzyme digestion.....	53
2.8.3.	DNA ligation.....	54
2.8.4.	Primer design.....	54
2.8.5.	PCR amplification of DNA.....	54
2.8.6.	PCR purification.....	55
2.8.7.	Agarose gel electrophoresis.....	55
2.8.8.	Agarose gel extraction.....	55
2.8.9.	Quantitation of DNA by quantitative PCR.....	55
2.8.9.1.	Quantitation of serum DHBV DNA by qPCR.....	56
2.8.9.2.	Quantitation of DHBV DNA in the liver by qPCR.....	56
2.8.9.3.	Mathematical calculation of the copy number of DNA.....	57
2.8.9.3.1.	Copy number of plasmid DNA per mass.....	57
2.8.9.3.2.	Copy number of duck DNA per cell.....	58
2.8.10.	DNA sequencing.....	58
2.8.11.	Cleanup of DNA sequencing products.....	58
2.8.11.1.	Isopropanol cleanup.....	58
2.8.11.2.	Magnesium sulphate cleanup.....	58
2.8.12.	DNA sequencing analysis.....	59
2.9.	Cloning.....	60

2.9.1.	Cloning of PCR products into the plasmid vector pCR 2.1-TOPO.....	60
2.9.2.	Analysis of PCR products cloned into the plasmid vector	60
2.9.3.	Plasmid glycerol stock.....	61
2.10.	Inverse nested PCR.....	61
2.10.1.	DNA inversion.....	61
2.10.2.	Low melting temperature agarose gel electrophoresis and purification of high MW cellular DNA followed by DNA inversion	62
2.10.3.	96-well nested PCR	62
2.10.4.	96-well agarose gel electrophoresis.....	63
2.10.5.	96-well agarose gel extraction.....	64
2.10.6.	96-well DNA sequencing	64
2.10.7.	Cleanup of 96-well DNA sequencing products.....	64
2.11.	Southern blot hybridisation	65
2.11.1.	Nitrocellulose membrane preparation	65
2.11.2.	³² P probe preparation.....	66
2.11.3.	Hybridisation of the ³² P-labelled probe to the nitrocellulose membrane	67
2.12.	Linker ligation assay.....	67
2.13.	Cell cultures.....	70
2.13.1.	Preparation of cell cultures	70
2.13.2.	Harvesting of cell.....	70
2.13.3.	Counting the number of cells.....	70
2.13.4.	DNA extraction from cells	71
2.13.5.	Calculation of cells present per 150 ng of DNA	71
2.14.	Fluorescence <i>in situ</i> hybridisation	71
2.14.1.	Preparation of metaphase chromosome spread slides	71
2.14.2.	Fluorescent probe preparation	72
2.14.3.	Hybridisation of the fluorescent probe	73
Chapter 3: Development of methods - Optimisation of DNA sequencing and qPCR protocols.....		92
Chapter 3.1: Optimisation of DNA sequencing.....		92
3.1.1.	Aim	92
3.1.2.	Introduction	92
3.1.3.	Generation of a standard DNA template for sequencing.....	93
3.1.4.	Optimisation of DNA sequencing reaction protocols	94
3.1.4.1.	Amount of DNA template per reaction	94
3.1.4.2.	Amount of BigDye Terminator mix per reaction	95

3.1.4.3.	Amount of sequencing buffer per reaction	96
3.1.4.4.	Final volume of the DNA sequencing reaction	97
3.1.4.5.	Comparison of methods to cleanup DNA sequencing products.....	97
3.1.4.6.	The effect of GelRed and ethidium bromide staining prior to DNA sequencing	99
3.1.5.	Conclusion	101
Chapter 3.2: Optimisation of qPCR assays		106
3.2.1.	Aim	106
3.2.2.	Introduction	106
3.2.3.	Linearisation of plasmid DNA for use in standard curves	108
3.2.3.1.	Linearisation of plasmid DNA using various amounts of restriction enzyme ..	108
3.2.3.2.	Generation of qPCR standard curves	109
3.2.3.3.	Quantitation of DHBV DNA using the generated standard curves.....	109
3.2.4.	Linearisation of plasmid DNA in the qPCR SYBR Green reaction mix for use in standard curves	111
3.2.4.1.	Optimisation of linearisation of plasmid DNA in the qPCR SYBR Green reaction mix	111
3.2.4.2.	Generation of qPCR standard curves	113
3.2.5.	Linearisation of DHBV DNA samples.....	115
3.2.6.	Standardisation of total amounts of DNA in each qPCR reaction	117
3.2.7.	Using pBL4.8 plasmid that contains a single copy of DHBV DNA as DNA template to generate qPCR standard curves	118
3.2.7.1.	Generation of qPCR standard curves	119
3.2.7.2.	Quantitation of DHBV DNA using the generated standard curves.....	119
3.2.8.	Conclusion.....	120
Chapter 4: Development of Methods - Establishment and optimisation of qPCR assays for the detection of duck DNA		135
4.1.	Aim	135
4.2.	Introduction	135
4.3.	Amplification and sequencing of duck genes.....	137
4.3.1.	Previous work performed to amplify and sequence the duck β actin gene	137
4.3.2.	Amplification and sequencing of the duck GAPDH gene.....	137
4.3.2.1.	Amplification and sequencing of a short fragment of the duck GAPDH gene, using known chicken GAPDH primers	137
4.3.2.2.	Amplification of a ~1 kbp fragment of the duck GAPDH gene, using primers designed based on the chicken GAPDH sequence	139

4.4.	Production and analysis of plasmids containing duck β actin and GAPDH genes	140
4.4.1.	Duck β actin gene	140
4.4.1.2.	Analysis of the cloned duck β actin gene sequence	141
4.4.2.	Duck GAPDH gene	142
4.4.2.1.	Production and analysis of pT2.1DgG plasmid containing duck GAPDH gene	142
4.4.2.2.	Analysis of the cloned duck GAPDH gene sequence	143
4.4.3.	Establishment of qPCR assays for the detection of duck β actin and GAPDH	145
4.4.3.1.	Optimisation of qPCR primers for duck β actin and GAPDH qPCR assays	145
4.4.3.1.1.	Optimisation of qPCR primers for the detection of duck β actin genes using pT2.1DgB plasmid as template	145
4.4.3.1.2.	Optimisation of qPCR primers for the detection of duck GAPDH genes using pT2.1DgG plasmid as template	147
4.4.3.2.	Calculation of plasmid copy numbers to generate qPCR standard curves	148
4.4.3.3.	Establishment of a qPCR standard curve for duck β actin and GAPDH using pT2.1DgB and pT2.1DgG plasmids	148
4.4.4.	Determining the copy numbers of duck β actin and GAPDH genes in duck cells	149
4.4.4.1.	Determining the copy number of duck β actin and GAPDH genes using qPCR	150
4.4.4.2.	Determining the copy numbers of duck β actin and GAPDH genes using FISH	152
4.5.	Discussion	153
4.6.	Conclusion	155
	Chapter 5: Development of methods for the invPCR assay	181
	Chapter 5.1: Extraction of cellular DNA from liver tissues	181
5.1.1.	Aim	181
5.1.2.	Introduction	181
5.1.3.	Non-selective and selective DNA extraction methods	183
5.1.3.1.	DNeasy blood and tissue kit	183
5.1.3.2.	ChargeSwitch gDNA mini tissue kit	184
5.1.3.3.	Total DNA extraction	185
5.1.3.4.	Low melting temperature agarose gel electrophoresis and purification of high MW cellular DNA	186
5.1.3.5.	Nuclear DNA extraction	187

5.1.3.5.1.	Optimisation of the nuclear DNA extraction method.....	187
5.1.3.6.	High MW DNA extractions.....	189
5.1.4.	Analysis of extracted DNA.....	190
5.1.4.1.	Amount and purity of total extracts.....	190
5.1.4.2.	Quality of extracts	194
5.1.4.3.	Inhibition of downstream reactions	195
5.1.4.3.1.	Restriction enzyme digestion	195
5.1.4.3.2.	PCR.....	196
5.1.4.4.	Quantitation of DHBV DNA and genomic DNA.....	196
5.1.5.	Conclusion.....	199
Chapter 5.2: The use of locked nucleic acid (LNA) oligonucleotides to increase the specificity of invPCR assays.....		210
5.2.1.	Aim	210
5.2.2.	Introduction	210
5.2.3.	Designing DHBV-specific LNA oligonucleotides	212
5.2.4.	The use of LNA oligonucleotides to block amplification of DHBV DNA from plasmid DNA templates	213
5.2.5.	Results and discussion.....	214
5.2.6.	Conclusion.....	216
Chapter 5.3: Using linker ligation assay to detect integrated virus-cell junctions		219
5.3.1.	Aim	219
5.3.2.	Introduction	219
5.3.3.	Using linker ligation assay to detect integrated virus-cell junctions in WHV-infected woodchuck liver tissues.....	220
5.3.3.1.	Woodchuck liver tissues.....	220
5.3.3.2.	Woodchuck linker ligation assay results	221
5.3.3.3.	Discussion.....	222
5.3.4.	Using linker ligation assay to detect integrated virus-cell junctions in DHBV-infected duck liver tissues	223
5.3.4.1.	Duck liver tissues	223
5.3.4.2.	Duck linker ligation assay results.....	224
5.3.4.3.	Discussion.....	225
5.3.5.	Conclusion.....	226
Chapter 5.4: Performing invPCR assays on plasmid DNA as a model system.....		238
5.4.1.	Aim	238
5.4.2.	Introduction	238

5.4.3.	Plasmid DNA as invPCR assay model system.....	239
5.4.4.	Establish invPCR assay – plasmid DNA template inversion step.....	240
5.4.4.1.	Restriction enzyme digestion of plasmid DNA.....	240
5.4.4.2.	Inversion of plasmid DNA	242
5.4.5.	Establish invPCR assay – nested PCR step.....	244
5.4.5.1.	Design of nested primer sets for inverted plasmid DNA	244
5.4.5.2.	Nested PCR amplifications of inverted plasmid DNA.....	244
5.4.6.	Parameters of invPCR assays assessed.....	247
5.4.6.1.	The sensitivity of detection of the invPCR assay	248
5.4.6.2.	The efficiency of the invPCR assay	249
5.4.6.3.	Product size preference during the invPCR assay.....	250
5.4.6.4.	The interference of duck cell DNA with the invPCR assay.....	252
5.4.6.5.	Taq polymerases combinations during nested PCR	253
5.4.7.	InvPCR assays detecting duck cellular genes as a model system	254
5.4.8.	Conclusion.....	256
Chapter 5.5: Performing invPCR assays on WHV-infected woodchuck and HBV-		
infected chimpanzee liver tissues.....		279
5.5.1.	Aim.....	279
5.5.2.	Introduction	279
5.5.3.	Woodchuck invPCR assay	279
5.5.3.1.	Woodchuck liver tissues.....	279
5.5.3.2.	Woodchuck invPCR assay design.....	280
5.5.3.3.	Woodchuck invPCR assay results.....	280
5.5.3.4.	Discussion.....	281
5.5.3.5.	Conclusion.....	282
5.5.4.	Chimpanzee invPCR assay.....	282
5.5.4.1.	Chimpanzee liver tissues	282
5.5.4.2.	Chimpanzee invPCR assay design	283
5.5.4.3.	Chimpanzee invPCR assay results	284
5.5.4.4.	Discussion.....	285
5.5.4.5.	Conclusion.....	286
Chapter 6: Establishment of invPCR assays to detect integrated virus-cell junctions in		
DHBV-infected duck liver tissues.....		307
6.1.	Aim.....	307
6.2.	Introduction	307

6.3.	Establishment of invPCR assays specific for the detection of integrated virus-cell junctions in DHBV-infected duck liver tissues	308
6.3.1.	Duck liver tissues collected in previous studies	308
6.3.2.	Determining the sequence of the most probable left and right hand end junctions of the integrated DHBV DNA	308
6.3.3.	Design of invPCR assays.....	310
6.3.4.	Extraction of liver cell DNA	311
6.3.5.	Performing the invPCR assay.....	311
6.3.6.	Establishing the duck invPCR assay	312
6.4.	Perform preliminary invPCR assays to detect integrated virus-cell junctions in DHBV-infected duck liver tissues.....	317
6.4.1.	Detecting integrated virus-cell junctions in liver tissues collected from ducks with acute DHBV infection	317
6.4.1.1.	Duck liver tissues collected from previous studies	317
6.4.1.2.	Results and discussion.....	319
6.4.2.	Detecting integrated virus-cell junctions in liver tissues collected from ducks with chronic DHBV infection	319
6.4.2.1.	Duck liver tissues collected from previous studies	319
6.4.2.2.	Results and discussion.....	321
6.5.	Analysis of the integrated virus-cell junctions detected.....	322
6.6.	Discussion on the efficiency of invPCR assay in detecting integrated virus-cell junctions in DHBV-infected duck liver tissues.....	324
6.7.	Conclusion.....	329
Chapter 7: The use of invPCR assays to explore the mechanisms involved in clearance of DHBV-infected hepatocytes during acute DHBV infection.....		348
7.1.	Aims	348
7.2.	Introduction	348
7.3.	To establish and monitor acute DHBV infection in ducks.....	352
7.3.1.	To establish acute DHBV infection in ducks	352
7.3.2.	Characterisation of histological and serological changes occurring during various stages of acute DHBV infection	354
7.3.2.1.	DHBsAg-positive hepatocytes in the liver	354
7.3.2.2.	Levels of inflammation in the liver	354
7.3.2.3.	Levels of hepatocyte apoptosis in the liver	357
7.3.2.4.	Levels of Kupffer cell infiltration and activation in the liver.....	358
7.3.2.5.	Levels of DHBsAg in the serum.....	360

7.3.2.6.	Levels of anti-DHBc antibodies in the serum	360
7.3.2.7.	Levels of anti-DHBs antibodies in the serum.....	361
7.3.2.8.	Levels of DHBV DNA in the serum	362
7.3.2.9.	Levels of DHBV DNA in the liver.....	363
7.4.	Using i nvPCR a ssay t o de tect i ntegrated vi rus-cell j uncti ons dur ing v ari ous stages of acute DHBV infection	364
7.4.1.	Sequence of the DHBV genome present in ducks.....	364
7.4.2.	Detection of integrated virus-cell junctions during various stages of acute DHBV infection using the invPCR assay	365
7.4.3.	InvPCR assay results	366
7.5.	Discussion.....	366
7.5.1.	Characterisation of histological and serological changes occurring during acute DHBV infection.....	366
7.5.2.	Detection of integrated virus-cell junctions using the invPCR assay.....	367
7.6.	Conclusion.....	369
Chapter 8: The use of invPCR to assess levels of clonal proliferation of hepatocytes during various stages of chronic DHBV infection		396
8.1.	Aims	396
8.2.	Introduction	396
8.3.	To establish and monitor chronic DHBV infection in ducks	398
8.3.1.	To establish chronic DHBV infection in ducks.....	398
8.3.2.	Characterisation of hi stological and s erological c hanges o ccurring dur ing various stages of chronic DHBV infection.....	400
8.3.2.1.	DHBsAg-positive hepatocytes in the liver	400
8.3.2.2.	Levels of inflammation in the liver	400
8.3.2.3.	Levels of hepatocyte apoptosis in the liver	402
8.3.2.4.	Levels of Kupffer cell infiltration and activation in the liver.....	404
8.3.2.5.	Levels of DHBsAg in the serum.....	406
8.3.2.6.	Levels of anti-DHBc antibodies in the serum	407
8.3.2.7.	Levels of anti-DHBs antibodies in the serum.....	408
8.3.2.8.	Levels of DHBV DNA in the serum	409
8.3.2.9.	Levels of DHBV DNA in the liver.....	409
8.4.	Using i nvPCR a ssay t o de tect i ntegrated vi rus-cell j uncti ons dur ing v ari ous stages of DHBV chronic infection.....	410
8.4.1.	Sequence of the DHBV genome present in ducks.....	410

8.4.2.	Detection of integrated virus-cell junctions during various stages of chronic DHBV infection using the invPCR assay.....	411
8.4.3.	InvPCR assay results	411
8.5.	Discussion.....	412
8.5.1.	Characterisation of histological and serological changes occurring during chronic DHBV infection.....	412
8.5.2.	Detection of integrated virus-cell junctions using the invPCR assay.....	413
8.6.	Conclusion.....	417
Chapter 9: Final discussion and concluding remarks		445
9.1.	Introduction	445
9.2.	Development of methods.....	446
9.3.	Development of the invPCR assay	447
9.4.	The use of invPCR assays to explore the mechanisms involved in clearance of DHBV-infected hepatocytes during acute DHBV infection in ducks.....	451
9.5.	The use of invPCR assay to assess levels of clonal proliferation of hepatocytes during various stages of chronic DHBV infection in ducks.....	455
9.6.	Future studies for characterisation of histological and serological changes occurring during acute and chronic DHBV infection.....	458
9.7.	Future directions to detect integrated virus-cell junctions using invPCR assay.....	462
9.8.	Concluding remarks.....	465
References.....		466

Ph.D. Candidate: Huey Chi LOW
Student ID: 1102743
Ph.D. thesis title: Molecular analysis of acute and chronic duck hepatitis B virus (DHBV) infections in ducks
Date: September 2012

Response to Ph.D. Thesis Examination

Brief statement from the candidate

Based on the Thesis Examination Reports, Examiner 1 did not specify any amendments to be made to the thesis, while Examiner 2 made extensive comments that needed to be addressed. This document thus details all the amendments made to the Ph.D. thesis in response to Examiner 2's comments.

Examiner 2's comments have been paraphrased from the Report and are shown below underlined. Each comment has been addressed individually. The page numbers referenced in this document are based on the page numbers of the amended thesis, which may vary from the page numbers mentioned by Examiner 2 in the Report (unless stated as "originally pages XX-XX", which refers to the page numbers in the original submitted thesis).

Detailed list of amendments made to the Ph.D. thesis in response to Examiner 2's comments

Layout of thesis

- 1.1. Include page numbers for Tables and Figures. Page numbers have been added for all Tables and Figures. The respective page numbers have been listed in a separate Table and Contents for Tables and Figures (refer point 2.1).
- 1.2. Integrate Tables and Figures into the text. Tables and Figures for each Chapter has not been integrated into the text and are placed at the end of each Chapter. This was to avoid disruption of the text, and for easy referencing as all the results were compiled together. To overcome the issue of difficulties in locating the Tables and Figures, page numbers for every Table and Figure have been included (as mentioned in point 1.1).
- 1.3. Reduce Figure sizes to include legend on the same page. Whenever possible, corresponding legends for Tables and Figures and were put on the same page.
- 1.4. Points were being repeated in different Chapters. Repeated information in later Chapters were removed and referred to previous Chapters. Some of the changes made have been listed below for each corresponding Chapter.
- 1.5. Results that were discussed in the Results section would not require a separate Discussion section, but can be finalised with a short conclusion. In all instances, discussion of results was moved from Results and put in the Discussion of each Chapter.
- 1.6. Layout of the thesis can be improved, e.g. integrate Chapter 5.2 with Chapter 6, and move Chapter 5.3 near to Chapter 6 to solve duplicated information in 6.3.1 and 5.3.4.1. After many considerations and testing of different Chapter/Section rearrangements, the original order of the thesis was still deemed the best and thus was maintained. The duplicated information issue was addressed in point 1.4.
- 1.7. Spelling out numbers in full when at the start of a sentence, or change the sentence structure so that it doesn't start with a number. All sentences starting with numbers were modified so that the numbers would not be at the beginning of a sentence. For instance, the sentence in Section 2.8.7 (page 55) "1% agarose gel was prepared" was changed to "To prepare 1% agarose gel". Other sentences that were modified include:
 - a) Abstract (page iv) 75.5%
 - b) Section 2.8.9 (page 56) 150 ng
 - c) Section 2.8.9.1 (page 56) 5 μ L
 - d) Section 2.8.9.2 (page 56) 150 ng
 - e) Section 2.10.2 (page 62) 600 μ L
 - f) Section 2.10.3 (page 63) 10 μ L
 - g) Section 2.10.5 (page 64) 100 μ L

- h) Section 2.10.6 (page 64) 4 μL
- i) Section 2.10.7 (page 64) 40 μL
- j) Section 2.11.1 (page 65) 2 sheets
- k) Section 2.11.2 (page 66) 50 μCi
- l) Section 2.11.2 (page 66) 150 ng
- m) Section 2.11.2 (page 66) 4 μL
- n) Section 2.11.3 (page 67) 12 mL
- o) Section 2.12 (page 67) 1 unit
- p) Section 2.12 (page 68) 10 μL
- q) Section 2.14.3 (page 72) 20 μL
- r) Figure 3.2.7 (page 133) 2
- s) Section 4.3.1 (page 137) 1023 bp
- t) Section 4.4.4.1 (page 150) 10-fold
- u) Figure 4.6 (page 170) 1122 bp
- v) Figure 4.9 (page 176) 1052 bp
- w) Figure 5.1.4 (page 207) 200 ng
- x) Figure 5.1.4 (page 207) 100 ng
- y) Figure 5.1.4 (page 207) 300 ng
- z) Figure 5.1.4 (page 207) 100 ng
- aa) Section 5.2.4 (page 213) 5 ng
- bb) Section 5.3.3.2 (page 221) 5 DNA sequencing reactions
- cc) Section 5.3.4.2 (page 224) 32 DNA sequencing reactions
- dd) Section 5.4.6 (page 247) 1 μg
- ee) Section 5.4.6.3 (page 250) 0.5 μg
- ff) Section 5.4.6.4 (page 252) 1 μg
- gg) Section 5.4.6.4 (page 252) 1 μg
- hh) Table 5.4.1 (page 257) ^a5 μg
- ii) Figure 5.4.3 (page 261) 5 μg
- jj) Figure 5.4.4 (page 263) 5 μg
- kk) Section 5.5.3.3 (page 280) 96-well
- ll) Section 5.5.3.3 (page 281) 7 DNA sequencing reactions
- mm) Section 5.5.3.3. (page 281) 5 DNA sequencing reactions
- nn) Section 5.5.4.3 (page 284) 96-well
- oo) Section 6.3.4 (page 312) 1.75 μg
- pp) Section 6.3.6 (page 313) 37 DNA sequencing reactions
- qq) Section 6.3.6 (page 314) 11 DNA sequencing reactions
- rr) Section 6.3.6 (page 315) 6 DNA sequencing reactions
- ss) Section 6.3.6 (page 316) 18 DNA sequencing reactions
- tt) Section 6.3.6 (page 317) 72 DNA sequencing reactions
- uu) Section 6.3.6 (page 317) 3 of the 4
- vv) Section 6.4.1 (page 318) 12 liver tissues
- ww) Section 6.6 (page 326) 5 DNA sequencing reactions
- xx) Section 6.6 (page 326) 6 DNA sequencing reactions
- yy) Section 6.6 (page 328) 10 DNA sequencing reactions
- zz) Section 6.6 (page 328) 15 DNA sequencing reactions
- aaa) Section 7.4.3 (page 367) 62 DNA sequencing reactions
- bbb) Section 8.5.2 (page 416) 2 of the integrated virus-cell junctions
- ccc) Section 8.6 (page 419) 3 integrated virus-cell junctions

1.8. Spell out the symbol “~” as “approximately” when at the start of a sentence. All sentences starting with symbols “~” and “+” were modified. For instance, the symbol in Section 2.6.4 (page 50) “~2 μg ” was changed to “Up to 2 μg ”. Other sentences that were modified include:

- a) Section 2.6.6.1 (page 51) ~25mg
- b) Section 2.11.1 (page 65) ~500 ng
- c) Section 2.12 (page 67) ~2 μg
- d) Figure 2.4 (page 83) “+”

- e) Figure 5.4.3 (page 261) ~1 µg
- f) Figure 5.4.4 (page 263) ~1 µg
- g) Figure 5.4.7 (page 269) ~1 µg
- h) Figure 5.4.8 (page 270) ~1 µg
- i) Section 6.3.2 (page 310) ~150 ng

2. Table of Contents

- 2.1. Add list of Tables and Figures. A secondary Table of Contents for Tables and Figures has been added after the primary Table of Contents and before the Abstract (page i).

3. Abstract

- 3.1. Incorrect formatting for Yang and Summers, 1999. The citation formatting errors for Yang and Summers on pages i, iv, v have been corrected. Other citation formatting errors that were not pointed out, for example Mason *et al.*, 2005 in page vi, have also been corrected.
- 3.2. Unexplained abbreviation “dpi” (page iii). The abbreviation “dpi” in page iii had already been previously explained in page i.

4. Chapter 1

- 4.1. Add page numbers for Tables and Figures, integrate Tables and Figures into text, reduce Figure sizes to include legend on the same page. These comments are respectively addressed in points 1.1, 1.2 and 1.3 above.
- 4.2. Quote original authors where possible, and insert “reviewed by...” when quoting review articles. Several citations were changed to the original authors. These include:
- a) Section 1.1 (page 1) Lok, 2000 → Blumberg *et al.*, 1967
 - b) Section 1.4 (page 8) Seeger and Mason, 2000; Jilbert *et al.*, 2008b → Stevens *et al.*, 1975
 - c) Section 1.4 (page 8) Andersson and Dienstag, 2008 → Beasley *et al.*, 1982
- Whenever original articles were not available, “reviewed by...” were added to the citations. These include:
- a) Section 1.2.2 (page 2) Kann, 2008
 - b) Section 1.2.4.1 (page 5) Jilbert *et al.*, 2008a; Yang *et al.*, 2010
 - c) Section 1.2.4.1 (page 5) Jilbert *et al.*, 2008a; Kann, 2008; Rabe *et al.*, 2009
 - d) Section 1.2.4.2 (page 5) Kann, 2008
 - e) Section 1.2.4.3 (page 6) Jilbert *et al.*, 2008a
 - f) Section 1.4 (page 8) Andersson and Dienstag, 2008
 - g) Section 1.4.1.2 (page 9) Lok, 2000; Visvanathan, 2008
 - h) Section 1.4.1.2 (page 10) Bowden, 2008
 - i) Section 1.4.2.1 (page 12) Funk *et al.*, 2002; Yim and Lok, 2006; Yuen and Lai, 2008
 - j) Section 1.4.2.2 (page 13) Bowden, 2008
 - k) Section 1.9 (page 23) Zoulim *et al.*, 2008
- 4.3. Citation “Jilbert *et al.*, 2008” should be labelled as either “2008a” or “2008b”. This error in citation have been corrected in the whole thesis, to correctly cite either Jilbert *et al.*, 2008a or Jilbert *et al.*, 2008b.
- 4.4. Length of Introduction was rather short, suggest including DHBV natural life cycle, experimental infection of ducks during acute and chronic DHBV infection, duck immune responses e.g. IFN as cytokine production may affect integration events. The overall length of Chapter 1 “Introduction” was not extended from its current length of 27 pages (1.5 paragraph spacing). An Introduction chapter of 25 – 30 pages (double spacing) has been the standard required length for a Ph.D. thesis in the Hepatitis Research Laboratory. Therefore, descriptions of the DHBV natural life cycle in the duck model were not included in Chapter 1, but are briefly described in Section 1.9 (page 24), and described in Chapters 6, 7 and 8 wherever necessary. The possible effects of cytokine/chemokine production on the rate of hepadnavirus integration have been included as a future study direction in Section 9.6 (page 460).
- 4.5. The ducks’ short lifespan (9-12 years) as a possible reason for ducks not developing HCC do not correlate with findings that woodchucks develop HCC within 4 years after infection. It was further clarified in Section 1.9 (pages 24-25) that woodchucks tend to develop HCC within 4

years after WHV infection due to the frequent activation of *N-myc* oncogenes so far only observed in the woodchucks. It was also clarified in Section 1.9 (pages 24-25) that compared to humans and chimpanzees, ducks have a short lifespan.

- 4.6. A better review of the relationship between HCC development and hepadnavirus integration is needed. The possible relationship between HCC development and hepadnavirus integration has already been addressed in Section 1.8 (page 22) and Section 9.5 (pages 456-458).
- 4.7. A better review of Section 1.8.1 "Detection of integrated virus-cell junctions" is needed. Section 1.8.1 had been expanded from 232 words to 840 words to briefly explain methods that had been used to detect integrated virus-cell junctions (pages 22-24). Description of Southern blot hybridisation and linker ligation assay was moved to Section 1.8.1 from Sections 8.2 and 5.3.2 respectively.

5. Chapter 2

- 5.1. Integrate Tables and Figures into text, reduce Figure size to include legend on same page, correct sentences that start with number or symbol. These comments are respectively addressed in points 1.2, 1.3, 1.9 and 1.10 above.
- 5.2. Figure 2.7 is unnecessary if space is a problem. Space was not a significant problem, thus Figure 2.7 (Figure 2.8 in the amended thesis) was retained.

6. Chapter 3

- 6.1. Integrate Tables and Figures into text, reduce Figure size to include legend on same page, correct sentences that start with number or symbol. These comments are respectively addressed in points 1.2, 1.3, 1.9 and 1.10 above.
- 6.2. Detailed descriptions of the optimization of existing assays are not required. The whole chapter needs to be rewritten and summarised, perhaps by tabulating the results. For Chapters 3.1 and 3.2, most of the results were already tabulated, or not included and merely described in-text if there were not a lot of data. The level of detail included in these Chapters was felt to be needed to justify the amount of work and level of detail scrutinized during the optimization of the DNA sequencing and subsequent cleanup of DNA sequencing products (Chapter 3.1), or during the optimization of qPCR assays for DHBV total and cccDNA (Chapter 3.2). Nonetheless, Chapter 3.1 was shortened from 11 pages (originally pages 61-70) to 10 pages (pages 92-101), while Chapter 3.2 was shortened from 18 pages (originally pages 72-89) to 15 pages (pages 106-120).
- 6.3. Figures 3.1.2 and 3.2.4 can be deleted. Figure 3.1.2 was omitted and simply described in-text in Section 3.1.4.6 (page 100). Figure 3.2.4 was kept as it showed evidence of over-digestion or non-specific digestions occurring when plasmid DNA were *EcoRI*-digested in the qPCR assay SYBR Green mastermix, something not previously performed and shown.

7. Chapter 4

- 7.1. Integrate Tables and Figures into text, reduce Figure size to include legend on same page, correct sentences that start with number or symbol. These comments are respectively addressed in points 1.2, 1.3, 1.9 and 1.10 above.
- 7.2. The sentence that "Clustal W2 alignment program was used" is repetitive and can be stated once at the beginning of the chapter. The repetitive sentences were removed from Sections 4.3.2.1 (pages 137-138), 4.4.1.2 (page 141), 4.4.2.2 (page 143), and simply referred to Section 2.8.12 (page 59) which had described the alignment program used in detail.
- 7.3. Chapter is verbose. Chapter 4 was shortened from 24 pages (originally pages 91-114) to 22 pages (pages 135-156).

8. Chapter 5.1

- 8.1. Too much discussion of advantages and disadvantages for each kit, some of which were repeated in the Results section. The discussion of the advantages and disadvantages of each DNA extraction method used in Section 5.1.3 were retained in order to give a more complete picture in determining the most suitable method to be used in the invPCR assay. The repeated discussions of the DNA extraction methods in the Results Section 5.1.4 (pages 190-199) were removed.

- 8.2. Section 5.1.4 Long discussion on accuracy of spectrophotometers is not needed. Comparison of Nanodrop spectrometer and Spectromax spectrophotometer in Section 5.1.4 (pages 190-191) was not to determine the accuracy of the Nanodrop spectrometer, but rather to show that this new equipment gives the same readings as the Spectromax spectrophotometer, which has been used in the Hepatitis Research Laboratory for many years. Thus, the results generated in this thesis could be confidently compared and even combined with previously generated results, without the potential differences of greater sensitivity or accuracy of the results obtained using the newer Nanodrop Spectrometry, as claimed by the manufacturer (Thermo Fisher Scientific, Canada). There is no doubt that the Nanodrop spectrometer is accurate. This Section was shortened, and some descriptions of the Nanodrop spectrometer was moved to Materials and Methods Section 2.8.1 (page 53).
- 8.3. Section 5.1.4.4 is mostly repetitive and can be deleted/summarised. Section 5.1.4.4 (pages 196-199) was one of the more important results for Chapter 5.1, as it looks to quantitate the levels of DHBV DNA and duck genomic DNA present in each extracted DNA sample. The ability to extract large amounts of duck genomic DNA with the least amounts of DHBV DNA is one of the main criteria for selecting a DNA extraction method to be used in the invPCR assay. Hence this Section was not removed. It was shortened from 1513 words (originally pages 132-135) to 1188 words (pages 196-199).
- 8.4. Detailed descriptions of the optimization of existing assays are not required and can be summarized in a table of results. Entire Chapter 5.1 was revised to be more succinct, with repeated information removed in subsequent paragraphs. Chapter 5.1 was shortened from 22 pages (originally pages 115-136) to 19 pages (pages 181-199).

9. Chapter 5.2

- 9.1. Some information in introduction has been repeated in discussions and thus can be removed. Entire chapter was revised to be more succinct, with repeated information removed in subsequent paragraphs. Chapter 5.2 was shortened from 8 pages (originally pages 137-144) to 7 pages (pages 210-216).

10. Chapter 5.3

- 10.1. Section 5.3.3.3 direct comparison of the linker ligation assay and the invPCR assay cannot be made as liver used was from different woodchucks. Direct comparison of the methods on the same liver samples was unfortunately not able to be performed due to the limited availability of in liver samples from the woodchucks. Instead, two woodchucks were chosen based on their similar WHV infection outcome and viral load, for as close a comparison as allowed. The discussion in Section 5.3.3.3 (page 222) was modified from a direct comparison of number of actual integrated virus-cell junctions detected, to the trend of the junctions detected. Statements were also included to note that both assays were compared using different liver samples.
- 10.2. Section 5.3.4.3 Provide details and reference to results of duck tissues mentioned here. Each duck invPCR assay results from Chapter 6 that was discussed in Section 5.3.4.3 was specifically referenced (pages 225-226).
- 10.3. Comment on the woodchuck and duck BLAST homology of integrated sites that included non target species homology. Statements were included in Section 5.3.3.2 (page 221) and 5.3.4.2 (pages 224) in regards to the BLAST homology to the insert DNA were not from the target species. This was due to the woodchuck and duck genome being not fully sequenced, and thus an insert DNA BLAST homology to other mammalian or avian species respectively would also be accepted. On a similar note, as the human genome has been fully sequenced and made accessible on GenBank, invPCR assay studies in humans would only accept any insert DNA with BLAST homology to humans as a true integration junction. InvPCR assay studies in chimpanzees similarly would also accept any insert DNA BLAST homology to humans as a true integration junction, based on the close evolutionary relationship between chimpanzees and humans (mentioned in Section 5.5.4.3 page 285).
- 10.4. Introduction Section 5.3.2 was shortened from 3 pages (originally pages 145-147) to 2 pages (pages 219-220), with discussions regarding the linker ligation assay moved to Introduction

Section 1.8.1 (pages 22-24). The entire Chapter was revised to be more succinct, with repeated information removed in subsequent paragraphs. Chapter 5.3 was shortened from 10 pages (originally pages 145-154) to 8 pages (pages 219-226).

11. Chapter 5.4

- 11.1. The entire Chapter was revised to be more succinct, with repeated phrases/sentences removed in subsequent paragraphs. Chapter 5.4 was shortened from 21 pages (originally pages 155-175) to 19 pages (pages 238-256).

12. Chapter 5.5

- 12.1. Section 5.5.4.1 Error in reporting that chimpanzee was 22 years old with history of chronic HBV for 27 years. Chimpanzee 4x222 was corrected to be “44 years old” at the time of biopsy (page 284).
- 12.2. Insertion of published papers. Hard copies of the two papers arising from contributions of results obtained in this Chapter were included in a pouch attached to the final bound Ph.D. Thesis. Soft copies (PDF files) of the two papers were also included in the CD containing the softcopy of the final Ph.D. Thesis.
- 12.3. Statement was included in Section 5.5.3.3 (page 281) that due to the woodchuck genome being not fully sequenced yet, for the woodchuck invPCR assay, an insert DNA BLAST homology to other mammalian species would be accepted. Another similar statement was included in Section 5.5.4.3 (page 285) that due to the close evolutionary relationship of chimpanzees and humans, for the chimpanzee invPCR assay, an insert DNA BLAST homology to either chimpanzee or human would be accepted.
- 12.4. Entire chapter was revised to be more succinct. Repeated information regarding invPCR assay and integration of viral dsDNA in Section 5.5.3.2 (page 280) were removed and referenced to Section 1.8.1 (pages 23-24). Chapter 5.5 was shortened from 10 pages (originally pages 177-186) to 8 pages (pages 279-286).

13. Chapter 6

- 13.1. Section 6.3.1 is a repeat of Section 5.3.4.1. The repeated information was removed (page 309) and reference back to Section 5.3.4.1 (page 223).
- 13.2. Section 6.3.2 Elaborate on whether the base pair differences of the DHBV sequences detected were near the 5' and 3' end and thus may affect the ability to detect integrated DHBV DNA. As shown in Figure 6.1 and described in Section 6.3.2, most mutations were at the first 35 nucleotide of the sequenced DHBV, one mutation was at nucleotide 502, and the rest were at the last 20 nucleotide of the sequenced DHBV. A statement was added in Section 6.3.2 that restriction enzymes for the duck invPCR assays should not have digestion sites at nucleotide 502, but the duck invPCR assay PCR primers could be designed to amplify across nucleotide 502 (pages 310-311). Based on Figure 6.4, for the chosen duck D3 invPCR assay design, the restriction enzyme digestion sites are at nucleotides 391, 505 and 526, while primer binding sites range from nucleotides 172 – 231 and 465 – 509. Thus, the mutations found in the DHBV sequences should not affect the restriction enzyme digestions, while PCR amplification should not be affected with a single base pair change at the primer binding site of nucleotide 502, and therefore would not affect the invPCR assay to detect integrated DHBV DNA.
- 13.3. Include headings for Table 6.3 with more information on the duck samples used. Headings with general information of the groups of ducks tested in this Section were added to Table 6.3 (page 337). Detailed explanations of each type of vaccination, antiviral treatment, time-points of liver biopsy, viral load etc. were not included, as the details of each duck were already mentioned in-text and referred to in the table legend, and would clutter and confuse Table 6.3 when included in the table heading.
- 13.4. Section 6.4.2.2 Query whether the invPCR assay was repeated for ducks FN76, FN77, FN78. A statement has been added to clarify that the invPCR assays had been repeated multiple times, all achieving similar results, which were no detectable invPCR products with only smears as seen by agarose gel electrophoresis (page 323).

- 13.5. Section 6.4.2.2 Query whether more work should be done in ducks FN1 and FN3 to determine the effect of antiviral therapy on viral integration. No further analysis of FN1 and FN3 liver samples were performed in this thesis, although future work could continue to analyse these liver samples to observe the possible effects of antiviral therapy on viral integration, clonal proliferation of hepatocytes, and formation of hepatocyte clones. A statement was added in Section 6.4.2.2 (pages 322-323) to note that “no further analysis was performed in this thesis although future work could continue to analyse these liver samples to observe the possible effects of antiviral therapy on viral integration, clonal proliferation of hepatocytes, and formation of hepatocyte clones”.
- 13.6. Section 6.6 Commented that invPCR results seemed variable, especially the DNA sequencing failure rates. Query whether Dr. Mason used exactly the same assay and methods, if so it would be the optimised methods. The methods performed in this thesis were initially slightly different from the methods used by Dr. Mason, due to the different availabilities of equipment in each lab (e.g. plate clamp, plate centrifuge), and potential differences in the quality of reagents used in each lab. Many strategies were suggested in Section 6.6 (pages 325-330) to improve the results obtained from the Hepatitis Research Laboratory. But it is true that sometimes some “batch variations” of invPCR assay results do occur at times, e.g. one batch of sequencing with have significantly more failed results compared to normal. In general however, sequencing reactions performed by Dr. Mason do have less failed results compared to sequencing reactions performed in this thesis.
- 13.7. Compare results using a table. Presentation of the results obtained from this thesis and from international collaborator Dr. William Mason as a table was not added. Although a table would definitely allow for direct comparison of both studies, there was too much information that would need to be included due to the many different samples and conditions of invPCR assays performed, causing the suggested table to be long and confusing.
- 13.8. Statement was included in Section 6.3.6 (page 313) that due to the duck genome being not fully sequenced yet, an insert DNA BLAST homology to other avian or mammalian species would also be accepted.
- 13.9. Entire chapter was revised to be more succinct. Chapter 6 was shortened from 27 pages (originally pages 187-213) to 24 pages (pages 308-331).

14. Chapter 7

- 14.1. The phrase “as there were no control ducks in this study...” was repeated numerous times. The control ducks used in this Chapter was described once in Section 7.3.1 (page 353), and removed from subsequent paragraphs, which only referred back to Section 7.3.1. All the other repeated information throughout the Chapter, like Section 7.3.2.9 (originally pages 231-232) that was repeated in Section 2.8.9.2 (page 57), was removed and referenced back to the corresponding previous Sections.
- 14.2. Table 7.1 The legend is too long. The histological grading system was moved to Section 2.4.1 (page 44), and simply referred to in the legends of Tables 7.1 (page 372).
- 14.3. Section 7.3.2.2 Query whether the ducks in this study were kept together as a group. If so, all ducks would be exposed to the same environmental toxins. All ducks in this study were kept together in the same housing pen. Explanations were added that the duck 342 with higher levels of liver injury due to environmental toxin was not due to exposure of only that duck in the whole group to the toxins, but rather the potential higher sensitivity and reactivity of that duck towards the toxins, compared to the other ducks (page 356).
- 14.4. Figure 7.5A DHBsAg levels were above the limit of detection between 25 and 36 dpi, but was referred to in Section 7.3.2.5 that they were below the limit of detection. The cut-off lines in Figures 7.5A, 7.5B and 7.5C (page 388) were misplaced. The positions of the cut-off lines have been corrected, and now correctly showing that the levels of DHBsAg were always below the level of detection throughout the study, as described in Section 7.3.2.5 (page 361)
- 14.5. Section 7.3.2.8 Comment that Vickery and Cossart (1996) J. Hepatology 25:504 found that peak viraemia could be delayed in older ducks until 15 dpi. Vickery and Cossart’s published study (1996) inoculated 26-day-old ducks with DHBV, which were much younger than the 42-day-old ducks used in this study. As the ducks in Vickery and Cossart (1996) were not age

matched, they were therefore not used for comparison in this Chapter. To emphasise that the comparisons made were with published age matched ducks only, the description “previously published age matched ducks” was included (page 363).

- 14.6. Move Section 7.6 to Chapter 9. The discussions of future directions from Section 7.6 (originally pages 239-243) were merged with Section 8.6 (originally pages 270-275) and moved to Sections 9.6 and 9.7 (pages 456-466), and replaced with a short “Conclusion” (pages 370-371).
- 14.7. Figure 7.7 (representation of primer binding sites on AusDHBV rcDNA) was moved to Chapter 2 as Figure 2.4 (page 83), as it was deemed more appropriate for this information to be placed in the Materials and Methods Chapter 2, which describes the qPCR methods and primers used for the amplification of the AusDHBV rcDNA.
- 14.8. Entire chapter was revised to be more succinct. Chapter 7 was shortened from 29 pages (originally pages 215-243) to 23 pages (pages 349-371).

15. Chapter 8

- 15.1. Section 8.2 Correction that male birds are homozygous for the sex chromosome, and not females as in the case for mammals. A statement clarifying that homozygous sex chromosomes are found in mammalian females but in avian males was added (page 398).
- 15.2. Chapter has repeated points from Chapter 7, e.g. Section 8.2 detection of integrated virus-cell junctions, Section 8.3.2.4 Kupffer cells and their staining, Section 8.4.1 reason for sequencing the DHBV genome, Section 8.5 reason for low detection rate of integrated virus-cell junctions etc. All repeated explanations, like in Sections 8.3.2.1 to 8.3.2.9, Section 8.4.1, Section 8.5.1, and Section 8.5.2 that had been previously mentioned in Chapter 7 were removed, and replaced with corresponding references to Chapter 7.
- 15.3. The phrase “as there were no control ducks in this study...” was repeated numerous times. The control ducks used in this Chapter was described once in Section 8.3.1 (pages 399-400), and removed from subsequent paragraphs, which only referred back to Section 8.3.1.
- 15.4. Section 8.4.3 typo that “4 integrated virus-cell junctions” should be “3”. Typo was corrected to “3 integrated virus-cell junctions” (page 412).
- 15.5. Section 8.5.2 Comment that preliminary work was done on neonatal ducks and thus may behave differently from this study. A note was added that the reported rate of DHBV integration published by Yang and Summers (1999) was obtained from a study of young 6-day-old ducks, and thus may be different to the rate of DHBV integration of 6-week-old ducks in this study (page 414).
- 15.6. Move Section 8.6 to Chapter 9. The discussions of future directions from Section 8.6 (originally pages 270-275) were merged with Section 7.6 (originally pages 239-243) and moved to Sections 9.6 and 9.7 (pages 456-466), and replaced with a short “Conclusion” (pages 418-419).
- 15.7. Section 8.5.2 Include more explanations addressing the reasons why Dr. Mason detected more integrated virus-cell junctions compared to this study. The reason that the “invPCR assay is not optimised” is not sufficient. Additional discussions regarding the differences of invPCR assays performed in this thesis compared to invPCR assays performed by collaborator Dr. Mason in the USA, that may have affected the low detection of integrated virus-cell junctions in this thesis, were included (page 417).
- 15.8. Section 8.5.2 Comment that Australian ducks may have differences in genetic makeup due to breeding in isolation for many generations, thus may affect the rate of viral integration compared to ducks from elsewhere in the world. Additional comment on the possible effects of the genetic makeup of ducks in this Australian study due to isolated breeding on the rates of DHBV integration into the genome have been added (page 416).
- 15.9. Link natural history of hepatitis in the various species to the quantity of integration sites detected. The ducks’ short lifespan as the reason for less integration junctions do not correlate with findings that woodchucks seemed to have the most integration sites in the same infection duration with ducks. Additional comments on the differences of the natural history of DHBV infection in ducks compared to other hepadnavirus infections in their natural hosts, in respect

to the different rates of DHBV integration into the genome and of clonal proliferation of hepatocytes have been added (pages 419-420).

- 15.10. The cut-off lines in Figure 8.5C (page 436) were misplaced. The positions of the cut-off lines have been corrected.
- 15.11. Entire chapter was revised to be more succinct. Section 8.2 (pages 397-399) was summarised and shortened, with details of the invPCR assay moved to Introduction Section 1.8.1 (pages 22-24). Chapter 8 was shortened from 31 pages (originally pages 245-275) to 23 pages (pages 397-419).

16. Chapter 9

- 16.1. Sections 7.6 and 8.6 “Future directions” were combined and summarised as new Sections 9.6 (pages 459-462) and 9.7 (pages 463-466).

17. References

- 17.1. PNAS should be shortened to Proc. Nat. Acad. Sci. This journal is commonly shortened as Proc. Nat. Acad. Sci. However, the abbreviation PNAS was still preferred in the context of this thesis, and have been defined in Abbreviations page xviii. Other journals, including the European Molecular Biology Organization (EMBO) and Public Library of Science (PLoS), have also been similarly abbreviated and defined in Abbreviations pages xv and xviii respectively.

Other amendments made to the Ph.D. thesis

1. The entire thesis was reviewed several times thoroughly and in greater depths to correct any typos, incorrect cross references, formatting errors, unexplained abbreviations, grammatical errors, and citation formatting errors that were not pointed out by the Examiners. The list of all changes made are not included in this document, as all the changes were minor and did not alter or affect any information or layout of the thesis.
2. The Declaration of originality and consent (page vii) was updated to the new Thesis Declaration as of July 2012 that was released by the Adelaide Graduate Centre, the University of Adelaide.
3. Section 1.3 “Animal models for the study of HBV” was moved to become Section 1.9 (pages 24-26) for a better flow in the Introduction Chapter 1.

Table of Content for Tables and Figures

Table 1.1	29
Figure 1.1	30
Figure 1.2	32
Figure 1.3	34
Figure 1.4	36
Figure 1.5	38
Table 2.1	74
Table 2.2	75
Table 2.3	77
Table 2.4	78
Figure 2.1	79
Figure 2.2	80
Figure 2.3	81
Figure 2.4	83
Figure 2.5	84
Figure 2.6	85
Figure 2.7	87
Figure 2.8	89
Figure 2.9	90
Table 3.1.1	102
Table 3.1.2	103
Figure 3.1.1	104
Table 3.2.1	121
Table 3.2.2	112
Table 3.2.3	122
Table 3.2.4	123
Table 3.2.5	124
Figure 3.2.1	125
Figure 3.2.2	127
Figure 3.2.3	129
Figure 3.2.4	130
Figure 3.2.5	131
Figure 3.2.6	132

Figure 3.2.7	133
Figure 3.2.8	134
Table 4.1	146
Table 4.2	157
Table 4.3	147
Table 4.4	158
Table 4.5	159
Table 4.6	160
Figure 4.1	161
Figure 4.2	163
Figure 4.3	164
Figure 4.4	166
Figure 4.5	168
Figure 4.6	170
Figure 4.7	172
Figure 4.8	174
Figure 4.9	176
Figure 4.10	177
Figure 4.11	179
Table 5.1.1	200
Table 5.1.2	201
Figure 5.1.1	202
Figure 5.1.2	203
Figure 5.1.3	205
Figure 5.1.4	207
Figure 5.1.5	209
Figure 5.2.1	217
Figure 5.2.2	218
Table 5.3.1	227
Table 5.3.2	228
Table 5.3.3	230
Table 5.3.4	232
Table 5.3.5	233

Figure 5.3.1	234
Figure 5.3.2	236
Table 5.4.1	257
Table 5.4.2	258
Figure 5.4.1	259
Figure 5.4.2	260
Figure 5.4.3	261
Figure 5.4.4	263
Figure 5.4.5	265
Figure 5.4.6	267
Figure 5.4.7	269
Figure 5.4.8	270
Figure 5.4.9	272
Figure 5.4.10	273
Figure 5.4.11	275
Figure 5.4.12	276
Figure 5.4.13	277
Table 5.5.1	287
Table 5.5.2	289
Table 5.5.3	292
Table 5.5.4	293
Figure 5.5.1	296
Figure 5.5.2	297
Figure 5.5.3	298
Figure 5.5.4	300
Figure 5.5.5	301
Figure 5.5.6	303
Figure 5.5.7	304
Figure 5.5.8	306
Table 6.1	332
Table 6.2	333
Table 6.3	336
Table 6.4	337
Table 6.5	339

Figure 6.1	340
Figure 6.2	342
Figure 6.3	344
Figure 6.4	346
Figure 6.5	347
Table 7.1	372
Table 7.2	374
Table 7.3	376
Table 7.4	377
Figure 7.1	378
Figure 7.2	380
Figure 7.3	382
Figure 7.4	384
Figure 7.5	386
Figure 7.6	388
Figure 7.7	390
Figure 7.8	392
Figure 7.9	394
Table 8.1	420
Table 8.2	422
Table 8.3	423
Table 8.4	425
Figure 8.1	426
Figure 8.2	428
Figure 8.3	430
Figure 8.4	432
Figure 8.5	434
Figure 8.6	436
Figure 8.7	438
Figure 8.8	440
Figure 8.9	442
Figure 8.10	444

Abstract

The hepadnavirus family contains two genera, Orthohepadnaviruses that infect mammals and Avihepadnaviruses that infect birds. The most thoroughly studied members of the hepadnavirus family include hepatitis B virus (HBV), which infects humans and chimpanzees, woodchuck hepatitis virus (WHV), which infects woodchucks, and duck hepatitis B virus (DHBV), which infects ducks. All hepadnaviruses have similar genome structure and organisation of the open reading frames on their genome, and also show extensive nucleotide sequence homology within, but not between, genera. All hepadnaviruses primarily infect hepatocytes and have similar infection outcomes in their natural hosts. The outcome of hepadnavirus infection can be divided into either acute, with successful clearance of infection from the host and establishment of immune control, or chronic, where infection is not cleared, resulting in persistent lifelong infection that is linked to various forms of liver disease.

The mechanisms involved in immune clearance of hepadnavirus infections are poorly understood. It has been hypothesised that virus DNA and proteins are, 1) cleared from the liver cytolytically by killing of the infected hepatocytes, or 2) can be destroyed non-cytolytically by cytokines, leaving the infected hepatocyte intact. In this study, the mechanism of immune clearance was explored using molecular approaches to detect integrated virus-cell junctions, formed by the integration of DHBV DNA into the duck liver genome. The rate of DHBV DNA integration is thought to be low (reported to occur at a rate of ~ 1 in $10^3 - 10^4$ cells by 6 days post infection (dpi)) (Yang and Summers, 1999), and the site of viral DNA integration into the host cell genome is random. Hence, each integration event will produce a unique integrated virus-cell junction that can be used as a genetic marker for that cell, which allows the fate of the DHBV-infected hepatocytes to be observed in the liver during various stages of both acute and chronic DHBV infection. Integrated virus-cell junctions can be detected using inverse nested PCR (invPCR), as described by Yang and Summers (Yang and Summers, 1999). Thus, this study aimed to determine whether cytolytic or non-cytolytic clearance of infected hepatocytes occurred, with the ultimate aim of contributing knowledge to assist in the development of new therapies for patients with chronic HBV infection.

Initially, several molecular assays required for the characterisation of DHBV infection and the invPCR assay were established and optimised. These included DNA sequencing reactions and subsequent purification of DNA sequencing products (Chapter 3.1), quantitative PCR (qPCR) assays used for the detection of DHBV total and cccDNA (Chapter 3.2), as well as cloning and sequencing of the duck beta actin (β actin) and glyceraldehyde-3-phosphate

dehydrogenase (GAPDH) genes. The latter were both used as internal controls in the qPCR assays to quantify levels of DHBV total and cccDNA per cell (Chapter 4). Several parameters were tested and compared for each molecular assay to generate final optimised protocols, which were then applied both throughout subsequent Chapters and in other work performed in the laboratory. The duck β actin and GAPDH genes were characterised and the sequences were submitted to GenBank (GenBank Accession GU564232 and GU564233 respectively).

The invPCR protocol was optimised by comparing 8 different liver cell DNA extraction methods, to determine the method that most efficiently extracted high molecular weight (MW) DNA from small quantities of frozen liver (Chapter 5.1). One of the major problems with the invPCR assay was the high level of virus-virus (false positive) sequences generated from replicative forms of virus DNA. Therefore, the use of locked nucleic acids (LNA) oligonucleotides that were specific for the DHBV genome were tested as a potential selective tool to block the amplification of DHBV DNA (Chapter 5.2). LNA oligonucleotides can bind with high affinity to their complementary DNA sequence, forming high melting temperature LNA-DNA complexes which then block amplification of that DNA sequence. Although the LNAs successfully blocked amplification of virus DNA, due to the high cost of LNA, their use in invPCR assays could not be pursued in this thesis. As a possible alternative to the invPCR assay, a linker ligation assay was assessed for its ability to detect integrated virus-cell junctions in samples of WHV-infected woodchuck and DHBV-infected duck liver tissue (Chapter 5.3). However, as the efficiency of detection of integrated virus-cell junctions using linker ligation assay was similar to the efficiency of the invPCR assay, it was not further developed in this thesis, as the linker ligation assay is more complicated and time-consuming than invPCR.

After optimising all the required molecular assays required for the invPCR assay in previous Chapters, the invPCR assay was first performed on plasmid DNA constructs as model systems, in order to determine the sensitivity and efficiency of the assay (Chapter 5.4). It was found that the invPCR assay was able to amplify from a single copy of DNA template. The invPCR assay was also performed on samples of WHV-infected woodchuck and HBV-infected chimpanzee liver tissue in collaboration with Dr. William Mason (Chapter 5.5). The results of the invPCR assay results confirmed that the assays established in this study had comparable efficiency with previously published invPCR assays, and could be confidently applied in this thesis. The integrated virus-cell junctions obtained in this study were included as a subset of the data published by Mason *et al.* 2009a and 2009b.

In order to establish an invPCR assay specifically for the AusDHBV strain (GenBank Accession AJ006350), several DHBV invPCR assays were designed, and preliminary studies were performed on liver tissues collected previously in the laboratory from ducks with acute and chronic DHBV infection (Chapter 6). Up to 38 integrated virus-cell junctions were successfully detected, among which 3 junctions were repeated, suggesting that clonal proliferation of hepatocytes had occurred in the duck liver. Characterisation of the integrated DHBV DNA showed that, consistent to previous studies, the most probable left and right hand end of the integrated DHBV dsDNA was at nucleotide position 2537 nt and ~2485 nt respectively, with no significant patterns or apparent preference of DHBV integration sites in the duck genome. The duck invPCR assay was subsequently extensively used in Chapters 7 and 8.

To achieve the main aim of this thesis, and to explore if cytolytic or non-cytolytic clearance occurs during the resolution of acute hepadnavirus infection, the invPCR assay was used to detect integrated virus-cell junctions during and after resolution of acute DHBV infection. This DHBV model provided an advantage over the WHV-infected woodchuck and the HBV-infected chimpanzee models, where hepadnavirus infection spreads to > 95% of the hepatocytes in the liver. Widespread infection requires the division of infected hepatocytes during clearance to replace hepatocytes killed by the host immune response. But in the duck model, DHBV infection can be established in ducks by inoculation with defined doses of DHBV to achieve a maximum DHBV infection of <10% of the hepatocytes prior to immune clearance. Therefore, when the few DHBV-infected hepatocytes were killed, they would be most likely be replaced by division of uninfected hepatocytes. It is thus expected that if cytolytic hepatocyte killing was the predominant response to DHBV infection, the integrated virus-cell junctions would not be detected in the recovered liver, as the infected hepatocytes would be destroyed and replaced by previously uninfected hepatocytes. Conversely, if non-cytolytic hepatocyte curing was predominant, the integrated virus-cell junctions would still be detected after clearance of infection as they would be present in the cellular genome of the “cured” hepatocytes.

Using AusDHBV, acute DHBV infections were established in 3, 6-week-old ducks (Chapter 7). At 4 dpi, active DHBV replication was occurring (159 and 3.6 copies of DHBV total and cccDNA per infected hepatocyte) with ~4.4% of DHBV surface antigen (DHBsAg)-positive hepatocytes in the liver. At 45 dpi, <0.001% of hepatocytes were DHBsAg-positive, with residual DHBV DNA predominantly in the cccDNA form (~0.02 copies and ~0.01 copies of DHBV total and cccDNA per liver cell). Histological characterisation of liver tissues showed

elevated levels of portal and lobular liver inflammation, hepatocyte apoptosis, and Kupffer cell infiltration and activation during clearance of infection (4 and 18 dpi), returning to “basal” levels after clearance (45 dpi). Serological characterisation revealed anti-DHBC antibodies by 4 dpi and anti-DHBs antibodies by 11 dpi. The neutralising anti-DHBs antibodies would have removed DHBV virions from the serum by forming antibody-antigen complexes to reduce the levels of viraemia, as only 2×10^6 copies of DHBV DNA was detected per mL of serum at 11 and 14 dpi. The anti-DHBs antibodies were also continuously produced at high levels after resolution of infection (45 dpi), providing protection against further DHBV infection.

Using the invPCR assay, up to 24.3 μg of DNA was analysed from liver tissues at 4, 18 and 45 dpi. However, no integrated virus-cell junctions were detected at any stages of acute DHBV infection out of the 286 invPCR products sequenced. Up to 75.5% of the invPCR products sequenced were found to be virus-virus (false positive) sequences. As DHBV DNA integration has been reported to occur at a rate of ~ 1 in $10^3 - 10^4$ cells by 6 dpi (Yang and Summers, 1999), out of the 9.7×10^6 cells analysed in this study, $\sim 4.4\%$ of which were DHBsAg-positive, it was expected that at least 40 – 400 integrated virus-cell junctions would be detected, assuming that the DHBV-infected hepatocytes were not cytolytically killed during resolution of infection. The failure to detect integrated DHBV-cell junctions in these studies could be due to several factors. Firstly, the high levels of invPCR assay false positives contributed by virus-virus sequences detected in this study (75.5% of total invPCR products) may have greatly reduced the efficiency of detection of the integrated DHBV-cell junctions. This could be improved by further optimisation of the invPCR assay, as well as the development of assays to reduce the detection of virus-virus sequences. Secondly, as the rate of integration was obtained from studies with ongoing high levels of active viral replication at ~ 6 dpi, the actual rate of integration in this study may be much lower than expected, and as DHBV infection were cleared by 18 dpi, this further shortened the timeframe for integration events to occur.

As an extension to the aims of this thesis, the molecular assays established in Chapters 3 to 6 were applied to study events occurring during chronic DHBV infection in ducks. In particular, the histological and serological changes occurring during different stages of chronic DHBV infection were characterised. In addition, changes in the hepatocyte population were studied by detecting integrated virus-cell junctions using the invPCR assay. As the frequency of the integrated virus-cell junctions would increase upon clonal proliferation of the infected hepatocytes, the size of hepatocyte clones formed and the rate of clonal proliferation of

hepatocytes could be determined by measuring the number of repeats for each integrated virus-cell junction. By establishing chronic DHBV infection in 6-week-old ducks, it was expected that chronic DHBV infection may be associated with increased levels of immune attack resulting in elevated levels of liver inflammation, hepatocyte apoptosis and activated Kupffer cells, as compared to ducks infected, for example, at 1 day of age. With a higher rate of immune attack and liver cell turnover, it was expected that hepatocyte clones would be formed in the liver by clonal proliferation of hepatocytes, as seen previously in studies performed in chronic hepadnavirus infection in humans, chimpanzees, and woodchucks.

Using the same AusDHBV virions, widespread and persistent DHBV infections (termed chronic DHBV infections) were established in 3, 6-week-old ducks (Chapter 8). At 4 dpi, active DHBV replication was occurring (219.5 and 3.7 copies of DHBV total and cccDNA per infected hepatocyte) with ~4.1% of DHBsAg-positive hepatocytes in the liver. At 18 dpi, the DHBV infection spread to >95% of hepatocytes in the liver, and was maintained until 165 dpi (duck 343) or 327 dpi (ducks 338 and 350), with continuous high levels of DHBV replication (181 – 298 copies of total DNA per liver cell) and viraemia (0.6 – 20 µg/mL DHBsAg; 1×10^6 – 1×10^9 copies of DHBV DNA per mL of serum), and the establishment of a pool of 5 – 9 copies of DHBV cccDNA per liver cell. Histological characterisation of liver tissues at 4 dpi showed elevated levels of portal and lobular liver inflammation and hepatocyte apoptosis, but with low levels of Kupffer cell infiltration and activation. By 18 dpi, widespread DHBV infection and marked portal and lobular liver inflammation and elevated levels of hepatocyte apoptosis and Kupffer cell infiltration and activation were observed in the liver. From 60 – 327 dpi, the levels of hepatocyte apoptosis and Kupffer cell activation persisted, while levels of liver inflammation and Kupffer cell infiltration decreased. Serological characterisation revealed anti-DHbC antibodies from 4 dpi, and anti-DHBs antibodies from 4 – 11 dpi, at low and varying titres. However, the anti-DHBs antibodies were not sufficient to complex to and remove the DHBV virions from the serum, as “active” viraemia was also detected, indicating that the levels of circulating DHBV virions in the serum were in excess of the anti-DHBs antibodies.

Using the invPCR assay, up to 22.8 µg of DNA were analysed from liver tissues at 4, 18 and 60, 165, 196, 327 dpi. Out of the 685 invPCR products sequenced, 3 integrated virus-cell junctions were detected, but no hepatocyte clones were found. 81% of the invPCR products sequenced were found to be virus-virus (false positive) sequences. As mentioned previously, integration of DHBV DNA has been reported to occur at a rate of ~1 in 10^3 – 10^4 cells by 6 dpi (Yang and Summers, 1999), thus out of the $\sim 8 \times 10^6$ cells analysed in this study,

with >95% of the hepatocyte population in the liver infected, it is expected that up to 800 – 8000 integrated virus-cell junctions would be detected, with hepatocyte clone sizes of at least 8 cells. Similar to results obtained in Chapter 7, the failure to detect more integrated DHBV-cell junctions in these studies could be due to high levels of virus-virus (false positive) sequences detected using the invPCR assay (81% of total invPCR products). It is of course possible that physiological differences between mammalian and avian liver biology could explain the lack of viral DNA integration and subsequent formation of hepatocyte clones. On top of that, as the timeframe of this study (327 dpi) was much shorter compared to 2.4 years post infection in woodchucks (Mason *et al.*, 2005) and at least 20 years post infection in humans and chimpanzees (Mason *et al.*, 2009a; Mason *et al.*, 2010), such large hepatocyte clones would not be expected to be found in ducks.

Declaration of originality and consent

I certify that this work contains no material which has been accepted for the award of any other degree or diploma in any university or other tertiary institution and, to the best of my knowledge and belief, contains no material previously published or written by another person, except where due reference has been made in the text. In addition, I certify that no part of this work will, in the future, be used in a submission for any other degree or diploma in any university or other tertiary institution without the prior approval of the University of Adelaide and where applicable, any partner institution responsible for the joint-award of this degree.

I give consent to this copy of my thesis, when deposited in the University Library, being made available for loan and photocopying, subject to the provisions of the Copyright Act 1968.

The author acknowledges that copyright of published works contained within this thesis resides with the copyright holder(s) of those works.

I also give permission for the digital version of my thesis to be made available on the web, via the University's digital research repository, the Library catalogue, and also through web search engines, unless permission has been granted by the University to restrict access for a period of time.

Huey Chi LOW

3rd April 2012

Publications and presentations resulting from this thesis

Manuscripts published

Mason, W., **Low, H.**, Xu, C., Aldrich, C., Scougall, C., Grosse, A., Clouston, A., Chavez, D., Litwin, S., Peri, S., Jilbert, A. and Lanford, R. (2009). Detection of clonally expanded hepatocytes in chimpanzees with chronic hepatitis B virus infection. Journal of Virology. 83(17): 8396-8408.

Mason, W., Xu, C., **Low, H.**, Saputelli, J., Aldrich, C., Scougall, C., Grosse, A., Colonno, R., Litwin, S. and Jilbert, A. (2009). The amount of hepatocyte turnover that occurred during resolution of transient hepadnavirus infections was lower when virus replication was inhibited with Entecavir. Journal of Virology. 83(4): 1778-1789.

Manuscript in preparation

Reaiche, G., Thorpe, M., **Low, H.**, Qiao, Q., Scougall, C., Mason, W. and Jilbert, A. Evidence that cccDNA survives mitosis during antiviral therapy for chronic hepadnavirus infections.

GenBank publications

Low, H., Reaiche, G., Jilbert, A. (2010) *Anas platyrhynchos* beta-actin gene, partial cds. GenBank Accession GU564232.

Low, H., Reaiche, G., Jilbert, A. (2010) *Anas platyrhynchos* glyceraldehyde-3-phosphate dehydrogenase-like protein (GAPDH) gene, partial cds. GenBank Accession GU564233.

Oral presentations

Low, H., Beard, M., Jilbert, A. Using integrated hepatitis B virus (HBV) DNA as genetic marker. School of Molecular and Biomedical Science PhD Symposium, Adelaide, July 2009.

Thorpe, M., Reaiche, G., **Low, H.**, Mason, W., Jilbert, A. Evidence that the episomal DNA that serves as the transcriptional template of duck hepatitis B virus is able to survive mitosis in the growing liver. International Hepatitis B Meeting, San Diego, USA, August 2008.

Low, H., Beard, M., Jilbert, A. Using integrated hepatitis B virus DNA as genetic marker for individual infected hepatocytes. The University of Adelaide PhD major review, Adelaide, September 2008.

Low, H., Grosse, A., Scougall, A., Aldrich, C., Xu, C., Hall, P., Clouston, A., Lanford, R., Mason, W., Jilbert, A. Detection of clonally expanded hepatocytes in chimpanzees with chronic hepatitis B virus infection. Australian Centre for HIV & Hepatitis Virology Research (ACH²) Annual Scientific Meeting, Barossa Valley, South Australia, June 2008.

Low, H., Mason, W., Jilbert, A. Using integrated hepatitis B virus DNA as genetic marker for individual infected hepatocytes. IMVS Infectious Diseases Laboratories (IDL) research seminar, Adelaide, July 2007.

Low, H., Mason, W., Jilbert, A. Using integrated hepatitis B virus DNA as a genetic marker of individual infected hepatocytes. The University of Adelaide Integrated Bridging Program (IBP) talk, Adelaide, June 2007.

Low, H., Mason, W., Jilbert, A. Using integrated duck hepatitis B virus DNA as a genetic marker for individual infected hepatocytes. Australian Centre for Hepatitis Virology (ACHV) Annual Workshop, Melbourne, May 2007.

Poster presentations

Low, H., Stroehrer, U., Mason, W., Jilbert, A. Using hepatitis B virus-cell junctions as genetic markers for individual infected hepatocytes. Australia Virology Group (AVG) Meeting, Lorne, Victoria, December 2009.

Low, H., Stroehrer, U., Mason, W., Jilbert, A. Using hepatitis B virus-cell junctions as genetic markers for individual infected hepatocytes. The University of Adelaide, School of Molecular & Biomedical Science School Research Symposium, Adelaide, December 2008.

Low, H., Mason, W., Jilbert, A. Using hepatitis B virus DNA as a genetic markers of individual infected hepatocytes. Australian Society for Microbiology (ASM) Annual Scientific Meeting, Adelaide, July 2007.

Award

Student travel award to the 2008 International Hepatitis B Virus meeting in San Diego, USA.

Acknowledgements

I would really like to take this opportunity to thank my principal supervisor, Associate Professor Allison Jilbert, for accepting me into the Hepatitis B Research family, and for all your hard work and constant guidance and advice (in science and even in life!) all these years. Thank you also for your patience and for believing in me. You have been a role model for me, and words just cannot express how much gratitude I have for what you have sacrificed and done for me. I am a better person and scientist today because of you! Thank you so much!

I would also like to thank my co-supervisors Associate Professor Michael Beard for your concern and support; and Dr. Uwe Stroehrer for having the patience in dealing with me, editing my thesis, and giving me the “kick-start” I really needed throughout this long torturous journey. Also not forgetting Dr. William Mason, who has been there with me from the very beginning, and have always been the person I can turn to when I need help with my research. Thank you so much for your patience, advice, for reading my thesis so willingly, and even for inviting me to visit your laboratory at the Fox Chase Cancer Center, USA. You truly have played a pivotal part in my research career. I am honoured to have known you.

To my fellow Hepatitis B Research “family members”, both past and present, THANK YOU! Dr. Georget Reaiche-Miller, what would I have done without you? To me, you have been my sister, friend, advisor, counsellor, support etc. throughout my entire laboratory years. I’m so grateful to have been given the privilege to study/work along you, and will sorely miss you. A big thank you also to Catherine Scougall, without whom the laboratory will not be running at all! Thank you for always silently and willingly going above and beyond in helping me in everything small and huge, for helping me so much with my duck studies, for your assurances and encouragement, and even for buying me breakfast and Fruchocs! I could not have done it without you. Not forgetting Dr. Behzad Baradaran for lending your expertise in veterinary in making my duck studies progress smoothly, and for your smile and encouragements; Dr. Feng Feng also for all your help with my duck studies, and all your advice and support in science and life, and Dr. Miao Yang for being part of my project. Arend Grosse, thank you so much for all the memorable times you created in your short time with us. You have opened my eyes to a whole new level of “laboratory efficiency”, and your photograph still hangs in the laboratory gently reminding us to “get back to work”. To my fellow PhD comrades, what can I say? Thomas Tu, I think I have spent too much time with you, that some of your “nerdiness” has unmistakably rubbed off on me. Thank you for being a wonderful friend, a sandbag for punching when things get tough, for filling in my huge gaps of knowledge in science, and

really just for being you. If it were up to me, I would have made you my co-supervisor! You really meant a great deal to me. Chee Quin Teoh, thanks also for being a friend and laboratory colleague by helping me with my duck and laboratory work, and being there for me all these years. Although as nice and memorable the experiences were, I think that I will not really miss the long journeys you used to make me undertake just to get lunch or bubble tea. Thank you Dr. Faseeha Noordeen for all your help with my duck studies, for the excellent and informative conversations over tea, and for being a great (and very responsible) companion on our conferences trips! To past Honours students, thank you so much Dr. Micheal Thorpe, for being a tremendous friend both in and out of the laboratory; Cui Xia (Tricia) Wang for providing me with some samples for my work and for your prayers; Hugh Trahair for being uniquely you and for all the once-in-a-lifetime moments I manage to experience with you around; Qiao (Eric) Qiao for inspiring me to be more hardworking and showing me what it takes to be a good scientist; Wen Ying (Layla) Zhu for being an irreplaceable friend both in and out of the laboratory, I really do not deserve the kindness you have shown me; and last but not least Sophie Trevor for your optimism, never-failing smile, and your ever memorable hilarious random comments. My time spent in the laboratory is truly irreplaceable.

I have also been very blessed to have the support from various people from the Molecular Life Sciences Building and the IMVS/SAP Pathology. Thank you to all past and present members of the Hepatitis C Research laboratory for being such understanding and friendly neighbours all these years, and for never failing to extend your help when I so needed it. To the academic staffs, especially in the department of Microbiology and Immunology, thank you for your support, guidance and counsel. It has been a memorable journey all the way from undergraduate level until today with you all. Dr. Jamie Botten, I will miss you so much! Thank you for being so encouraging, so patient with me and entertaining my ranting about Star Wars and LEGO, for spoiling me with gifts, and most importantly being my role model as a Christian and a scientist. A huge thank you also to Dr. Christopher Wong for helping me so much both in and out of the laboratory, for the printing of figures in this thesis, for sharing your knowledge with me, and for all the opportunities you have provided for me to teach. My gratitude also goes out to all the general staff of the Molecular Life Sciences Building, in administration, at the store or at Central Services Unit, for all your help and support to make everything run smoothly around the school. Not forgetting Garry Penney for being like a “handyman”, helping me out with all sorts of random favours throughout all these years, and for always smiling and being the friendliest person around. To fellow PhD comrades both past and present: Elizabeth Tran, Sophia Tan, Damien Chong, Magdalene Papadopoulos, Min Yan Teh, Shu Ly Lim, May Huey Tan, Donald Jiang, Mabel Lum and many others, thank you for

being such wonderful friends and for all your support, food-fixes (CHOCOLATE!!), and wonderful, memorable times we have had together! Last but not least, my gratitude goes out to all the staff members at the Animal Facility of the IMVS/SA Pathology for all your assistance, providence and patience; to the team at the Tissue Pathology Laboratories of the IMVS/SA Pathology, especially Sophie Kogoj for helping me tirelessly with the tissue cutting and staining, Dr. Tuck Weng Kok for your friendly advice and counsel, Dr. Robert Ratcliff and the team at the Sequencing Facilities for your help with DNA sequencing.

I would also like to take this opportunity to thank the people outside of the university boundaries that have been pivotal to me throughout my journey. To my parents, thank you so much for allowing me to pursue my studies and for supporting me unceasingly. I really appreciate everything that you have sacrificed for me, and I love you both so, so much. To my elder sister, thank you for doing what siblings do best – always being there for me, encouraging and making me laugh, and even for trying to help although you do not understand “science”. I am so thankful to have a sister like you. Yee Ming (Isaac) Lam, thank you so much for your undeserving love, patience, support, encouragement, delicious Neslo drinks, pampering, sacrifice to let me complete my PhD, prayers, for understanding my needs in this long journey, and the list goes on and on. I really thank God for you, and cannot wait to go on greater adventures with you! To my grandmother, aunties, uncles and cousins, thank you so much for your support and love. Also not forgetting Amber the cat, for keeping me company and warm all those long, lonely nights, and for having the gift of taking all my troubles away by just a meow, a pat, a stare, or a hug. Ah Ann the cat, I miss you a lot too. You both truly are the little angels in my life.

My gratitude also goes out to my housemates both past and present. Thank you Ruby and Samuel (Miguel-)Lai for bringing order into my chaotic life, for your prayers and sacrificial help all these years. Jezamine Chan, man, I will not be “alive” today if it were not for you! You really mean a lot to me, and living with you is one of the best things that have ever happened to me. To fellow IDKA household members who keep me young: thank you Katrina Ng for being like a big sister to me, for feeding me with all those yummy food, for your patience, and for your randomness that never fails to amuse me; and Wen Chian Chen for caring for me so much, selflessly lending me your things, and tolerating with my crazy antics around the house. I also cannot forget my “pseudo-housemates” – fellow members of the A JIN household. Thank you James Lam, Norman Seah, James Quah, Erwin Lee and Caleb Mamman for bearing with me and allowing me into your house so often. Thank you for looking after and spoiling Amber the cat, and for all those irreplaceable times we had together.

I also could not have done it if it were not for my brothers and sisters in Christ. To Ailyn, Wally, Natalie and Jeremy Hanin, thank you so much for being like a second family to me! Thank you for feeding me, looking after me, and supporting me in every ways big and small throughout my entire stay in Adelaide. I will really miss you all a lot. Thank you to the Pastors who have been praying for me and supporting me all these time, especially Phyllis Lines, Ernest and Bee Bee Lee and their household, (Aunty) Merylyn Teague, Tim Wallis and his household, Michael and Chew Har Raj and their household. Thank you so much everyone at Influencers Church (formally Paradise Community Church) and Living Water Baptist Church! Lastly to everyone from Overseas Christian Fellowship, current or former, from the three South Australia centres and every centre throughout Australia, and especially to my EXCO comrades who are exceptionally dear to me, thank you so much for being like a family to me, and playing a huge part in my life! I am sorry that I cannot name you all personally, but I treasure you all no less than others. It has been an amazing and honour being on this journey with you all, and I have grown so much because of you all. I will sorely miss the support, your prayers, the crazy times we had, our sharings, and the amazing fellowship.

Last but not least, I would like to give all the glory to God my Father. Thank You for letting me be part of Your family through Your Son, and for sending the Counsellor to guide me and to give me wisdom. Thank You for Your unchanging, underving love, and for being my comforter who wipes away all those tears, my strength when I cannot take another step, my provider till overflowing, my support and my shelter from anxiety, my all in all, and being with me so that I did not have to go through it alone. Thank You also for reminding me that this thesis is a gift from You, and that it was not done by my strength or my might, that I may boast in my abilities. *When I said, "My foot is slipping," your love, O LORD, supported me. When anxiety was great within me, your consolation brought joy to my soul. Psalm 94:18-19.*

Abbreviations

μ	micro
<	less than
~	approximately
°C	degree Celsius
%	percent
1H.1	mouse anti-DHBV preS antibodies, IgG2a subtype
2' CDG	2' carbodeoxyguanosine
A	adenine
A	Ampere
AB	Applied Biosystems, now part of Life Technologies
AEC	Animal Ethics Committee
AGRF	Australian Genome Research Facility
ALT	alanine aminotransferase
AR	analytical reagent
AST	aspartate-aminotransferase
AU	Anson unit
AusDHBV	Australian strain of DHBV, Genbank Accession AJ006350
b	base(s)
BD	Becton Dickinson
BLAST	Basic Local Alignment Search Tool
bp	base pair(s)
BrdU	Bromodeoxyuridine
BSA	bovine serum albumin
c	centi
C	cytosine
C	core
CaCl ₂	calcium chloride
cccDNA	covalently closed circular DNA
CDC	Centers for Disease Control and Prevention
cDNA	complementary DNA
Ci	curie
CMI	cell mediated immunity
CPM	counts per minute
CSU	Central Services Unit, the University of Adelaide, SA

CTL	cytotoxic T-lymphocyte
DAB	diaminobenzidine tetrahydrochloride
DAPI	4',6-diamidino-2-phenylindole
ddNTP	dideoxy nucleotide tri-phosphate
DHBcAg	duck hepatitis B core antigen
DHBsAg	duck hepatitis B surface antigen
DHBV	duck hepatitis B virus
DMSO	dimethyl sulfoxide
DNA	deoxyribo nucleic acid
dNTP	deoxy nucleotide tri-phosphate
DOP PCR	semi-degenerate oligonucleotide-primed PCR
dpi	day(s) post infection
DR	direct repeat
dsIDNA	double stranded linear DNA
dUTP	deoxyuridine tri-phosphate
EAA	ethanol:acetic acid (3:1 v/v)
EB	elution buffer
EDTA	ethylenediaminetetraacetic acid
ELISA	Enzyme-Linked ImmunoSorbent Assay
EMBO	European Molecular Biology Organization
<i>E. coli</i>	<i>Esterichia coli</i>
ER	endoplasmic reticulum
ETV	entecavir
FCCC	Fox Chase Cancer Center, Philadelphia, USA
FCS	foetal calf serum
FTC	emtricitabine
g	gram(s)
g OR x g	x gravitational force, or known as RCF
G	guanine
GAPDH	glyceraldehyde 3-phosphate dehydrogenase
GE	genome equivalents
GE	General Electric Company, Sweden
GSHV	ground squirrel hepatitis virus
H&E	haematoxylin and eosin
H ₂ O	water
H ₂ O ₂	hydrogen peroxide

H ₂ SO ₄	sulphuric acid
HAART	highly active antiretroviral therapy
HBcAg	HBV core antigen
HBeAg	hepatitis B e surface antigen
HBsAg	HBV surface antigen
HBV	hepatitis B virus
HBxAg	hepatitis B X protein
HCC	hepatocellular carcinoma
HCl	hydrochloric acid
HCV	hepatitis C virus
HI	digested at high concentrations
HIV	human immunodeficiency virus
HNF	hepatocyte nuclear factor
HPRT1	hypoxanthine-guanine phosphoribosyl transferase I
hr	hour(s)
HRP	horseradish peroxidase
IFN	interferon
IgY	immunoglobulin Y
IL	interleukin
IMVS	Institute of Medical and Veterinary Science, SA Pathology
invPCR	inverse nested PCR
IU	International Unit
k	kilo
kb	kilo base pairs
KCl	potassium chloride
L	litre(s)
LB	Luria broth
LHB	large hepatitis B surface proteins
LNA	locked nucleic acid
LO	digested at low concentrations
m	metre(s)
m	mili
M	molar(s)
M	mega
MCS	multiple cloning site

MgCl ₂	magnesium chloride
MgSO ₄	magnesium sulphite
MHB	middle hepatitis B surface protein
MHC	major histocompatibility complex
mIU	mili International Unit(s)
min	minute(s)
mol	mole
mRNA	messenger RNA
MW	molecular weight
n	nano
N/A	not available
NA	nucleoside/nucleotide analogue(s)
Na ₃ Citrate	trisodium citrate
NaCl	sodium chloride
Na ₂ HPO ₄	disodium hydrogen phosphate
NaH ₂ PO ₄	monosodium phosphate
NaN ₃	sodium azide
NaOAc	sodium acetate
NaOH	sodium hydroxide
NCBI	National Center for Biotechnology Information
ND	not detected
NDS	normal duck serum
NEB	New England Biolabs, USA
NHMRC	National Health and Medical Research Council, Australia
NK	natural killer
no.	number
NP40	nonyl phenoxy polyethoxy ethanol Tergitol-type NP-40
NSS	normal sheep serum
NSW	New South Wales, Australia
nt	nucleotide(s)
OD	optical density
OH&S	Occupational Health and Safety
OPD	o-phenylenediamine dihydrochloride
ORF	open reading frames
p	pica
P	polymerase

PAMPs	pathogen-associated molecular patterns
PAS-D	periodic acid-Schiff diastase
PBMC	peripheral blood mononuclear cells
PBS	phosphate buffered saline
PBS-T	phosphate buffered saline- tween
pBsSK	pBluescript SK II - plasmid
PCNA	proliferating cell nuclear antigen
PCR	polymerase chain reaction
pfu	plaque forming units
PLoS	Public Library of Science
PNAS	Proceedings of the National Academy of Sciences of USA
PVP	polyvinylpyrrolidone
qPCR	quantitative PCR
rcDNA	relaxed circular DNA
RCF	Relative Centrifugal Force
RI	replicative intermediates
RNA	ribonucleic acid
RNase	ribonuclease
rpm	revolutions per minute
RT	reverse transcription
RT	room temperature
S	surface
SA	South Australia, Australia
SAP	shrimp alkaline phosphatase
SDS	sodium dodecyl sulphate
sec	second(s)
SHB	small hepatitis B surface protein
SOX5	Or1 sex determining region Y-box 5
T	thymine
TAE	tris acetate EDTA
TBP	TATA-binding protein
TE	tris EDTA
TFV	tenofovir
Th1	type 1 T helper cells
Th2	type 2 T helper cells
TLR	Toll-like receptors

T _m	melting temperature
TNF	tumour necrosis factor
TNFV	tenofovir
Tris HCl	tris(hydroxymethyl)aminomethane
TUNEL	terminal deoxynucleotidyl transferase dUTP nick end labelling
U	unit(s)
ULN	upper limit of the normal range
USA	the United States of America
UV	ultraviolet
V	Volt(s)
vge	virus genome equivalent
WHO	World Health Organization
WHV	woodchuck hepatitis virus
x	time(s)
YY1	Yin and Yang 1